SCHEMBL3065853

SCHEMBL3065853

OC(CCl)CN1CCCCC1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.73
KMT2A Q03164 2/20 0.73
ATM Q13315 2/20 0.60
MAPT P10636 1/20 0.60
HSD17B10 Q99714 1/20 0.53
CYP2D6 P10635 2/20 0.47
CYP2C19 P33261 1/20 0.47
TSHR P16473 2/20 0.45
POLB P06746 3/20 0.44
HIF1A Q16665 1/20 0.44
RAD52 P43351 1/20 0.44
NLRP1 Q9C000 1/20 0.44
KDM4E B2RXH2 3/20 0.43
ACE2 Q9BYF1 1/20 0.43
ALDH1A1 P00352 1/20 0.43
USP2 O75604 1/20 0.43
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9477321 1.00 MEN1 (0.73) MEN1KMT2AATMMAPTHSD17B10
Hydrochloric Acid SCHEMBL5887775 0.98 MEN1 (0.70) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL488808 0.98 MEN1 (0.68) MEN1KMT2AATMMAPTHSD17B10
Hydrochloric Acid SCHEMBL6550173 0.95 KMT2A (0.65) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL9819626 0.87 MEN1 (0.52) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL8391173 0.87 MEN1 (0.52) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL11118757 0.85 MEN1 (1.00) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL10895166 0.82 MEN1 (0.94) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL16625789 0.80 MEN1 (0.90) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL64167 0.78 ATM (0.95) MEN1KMT2AATMMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267711-A1 METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF CYTRX CORPORATION (US) 2010-10-21 US disclosed
US-7745465-B2 Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof CYTRX CORPORATION (US) 2010-06-29 US disclosed
US-7148239-B2 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof CYTRX CORPORATION (US) 2006-12-12 US disclosed
CN-1152871-C Hydroxylamine derivatives for enhancing the production of molecular chaperones and preparation thereof �ݰ��п�˹�о���չ��˾ 2004-06-09 CN disclosed
US-20040067940-A1 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof BIOREX RESEARCH & DEVELOPMENT CO. 2004-04-08 US disclosed
US-20040019103-A1 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof BIOREX RESEARCH & DEVELOPMENT CO. 2004-01-29 US disclosed
US-6653326-B1 For example, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-3-pyridinecarboximidoyl chloride maleate; inducing gene expression of an eukaryotic cell under physiological stress; antiallergens; autoimmune diseases; cardiovascular disorders BIOREX RESEARCH & DEVELOPMENT CO. (HU) 2003-11-25 US disclosed
EP-0801649-B1 HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF BIOREX KUTATO FEJLESZTOE KFT (HU) 2002-08-07 EP disclosed
EP-0832079-B1 ANTI-ISCHAEMIC HYDROXYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS BIOREX KUTATO FEJLESZTOE KFT (HU) 2002-03-27 EP disclosed
US-6180787-B1 Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides BIOREX KUTATO ES FEJLESZTO RT. (HU) 2001-01-30 US disclosed
US-5296606-A O-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same BIOREX KUTATO-FEJLESZTO KFT (HU) 1994-03-22 US disclosed
EP-0417210-B1 NOVEL O-(3-AMINO-2-HYDROXYPROPYL)-HYDROXIMIC ACID HALIDES AND PROCESS FOR PREPARING THE SAME BIOREX KUTATO FEJLESZTOE KFT (HU) 1994-03-09 EP disclosed
US-5218117-A Antiallergens, antiinflammatory agents CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1993-06-08 US disclosed
US-5179089-A Antiallergens, asthma CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1993-01-12 US disclosed
US-5147879-A O-(3-AMINO-2-HYDROXYPROPYL)-HYDROXIMIC ACID HALIDES AND PROCESS FOR PREPARING THE SAME BIOREX KUTATO-FEJLESZTO KFT (HU) 1992-09-15 US disclosed
EP-0486211-A1 Isoquinoline derivatives CHINOIN Gyògyszer és Vegyészeti Termékek Gyára RT. (HU) 1992-05-20 EP disclosed
EP-0417210-A1 NOVEL O-(3-AMINO-2-HYDROXYPROPYL)-HYDROXIMIC ACID HALIDES AND PROCESS FOR PREPARING THE SAME. BIOREX KUTATO FEJLESZTOE KFT (HU) 1991-03-20 EP disclosed
WO-1990004584-A1 NOVEL O-(3-AMINO-2-HYDROXYPROPYL)-HYDROXIMIC ACID HALIDES AND PROCESS FOR PREPARING THE SAME BIOREX KUTATÓ FEJLESZTO^' KFT. (HU) 1990-05-03 WO disclosed
US-4308399-A O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1981-12-29 US disclosed
US-4187220-A New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA R.T. (HU) 1980-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267711-A1 METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF HSPE1, HSF1, HSP90AB2P MEN1 4335/4885KMT2A 3924/4885ATM 3403/4885
US-20040019103-A1 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof HSPE1, HSF1, HSPA1A MEN1 4141/4885KMT2A 3889/4885ATM 3134/4885
US-20040067940-A1 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof HSPE1, HSF1, HSPA1A MEN1 4141/4885KMT2A 3889/4885ATM 3134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.